Common Contracts
72 similar Underwriting Agreement contracts by Orthopediatrics Corp, Aziyo Biologics, Inc., Biolase, Inc, others
•] Shares Chain Bridge Bancorp, Inc. Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 30th, 2024 • Chain Bridge Bancorp Inc • National commercial banks • New York
Chain Bridge Bancorp, Inc., a Delaware corporation (the “Company”), the holding company for Chain Bridge Bank, N.A. (the “Bank”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) of Class A common stock, $0.01 par value per share (the “Class A Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to [•] additional shares of Class A Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Shares.” The shares of Class B common stock, $0.01 par value per share, of the Company are hereinafter referred to as the “Class B Common Stock.” The Class A Common Stock and the Class B Common Stock are collectively hereinafter referred to as the “Common Stock.”
5,374,755 Shares1 Nyxoah SA Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 24th, 2024 • Nyxoah SA • Surgical & medical instruments & apparatus • New York
Nyxoah SA, a limited liability company (naamloze vennootschap/société anonyme) organized under the laws of Belgium (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,374,755 Ordinary Shares (the “Firm Shares”), with no nominal value (the “Ordinary Shares”), of the Company. The Company has also granted to the Representative an option to purchase up to 806,213 additional Ordinary Shares on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
5,250,000 Shares1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • July 27th, 2023 • NEUROONE MEDICAL TECHNOLOGIES Corp • Surgical & medical instruments & apparatus • New York
NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”) proposes to sell to The Benchmark Company, LLC (the “Underwriter”) an aggregate of 5,250,000 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company has also granted to the Underwriter an option to purchase up to 787,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
6,250,000 Shares Miromatrix Medical Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 8th, 2023 • Miromatrix Medical Inc. • Biological products, (no disgnostic substances) • New York
22,225,000 Shares ATYR PHARMA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2023 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
aTyr Pharma, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 22,225,000 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 3,333,750 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
FORM OF UNDERWRITING AGREEMENT BIOLASE, INC.Underwriting Agreement • January 3rd, 2023 • Biolase, Inc • Dental equipment & supplies • New York
Biolase, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters” or each, an “Underwriter”) an aggregate of (x) [•] shares (each a “Firm Share” and collectively, the “Firm Share”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and (y) [•] pre-funded common stock purchase warrants of the Company (each a “Firm Pre-Funded Warrant” and collectively, the “Firm Pre-Funded Warrants”), with each Firm Pre-Funded Warrant exercisable to purchase one share of Common Stock at an exercise price of $0.01 per share. The Firm Shares and the Firm Pre-Funded Warrants are collectively referred to herein as the “Firm Securities”. The Company also proposes to sell to the Underwriters in any combination, at the option of the Representative, up to an additional (i) [•] shares of Common Stock (the “Option Shares” and, collectively with the Firm Shares, the “Shares”), and (ii) [•] pre-fu
FORM OF UNDERWRITING AGREEMENT BIOLASE, INC.Underwriting Agreement • December 12th, 2022 • Biolase, Inc • Dental equipment & supplies • New York
Biolase, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters” or each, an “Underwriter”) an aggregate of (x) [•] units of the Company (each a “Unit” and collectively, the “Units”), with each Unit consisting of (i) one share (each a “Firm Share” and collectively, the “Firm Share”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and (ii) one common stock purchase warrant of the Company (each a “Firm Warrant” and collectively, the “Firm Warrants”), with each Firm Warrant exercisable to purchase one share of Common Stock (the “Firm Warrant Shares”), at an exercise price of $[•] per share, subject to adjustment therein, and (y) [•] pre-funded units of the Company (each a “Pre-Funded Unit” and collectively, the “Pre-Funded Units”), with each Pre-Funded Unit consisting of one pre-funded common stock purchase warrant of the Company (each a “Firm Pre-Funded Warrant” an
2,350,000 Shares1 Aziyo Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 5th, 2022 • Aziyo Biologics, Inc. • Biological products, (no disgnostic substances) • New York
Aziyo Biologics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,350,000 shares (the “Firm Shares”) of Class A common stock, $0.001 par value per share (the “Class A common stock” and together with the Company’s Class B common stock, $0.001 par value per share, the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 352,500 additional shares of Class A common stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
2,275,000 Shares OrthoPediatrics Corp. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 12th, 2022 • Orthopediatrics Corp • Surgical & medical instruments & apparatus • New York
OrthoPediatrics Corp., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) 750,000 shares (the “Firm Shares”) of Common Stock, $0.00025 par value per share (the “Common Stock”) and (ii) 1,525,000 pre-funded warrants to purchase up to an aggregate of 1,525,000 shares of Common Stock (the “Pre-Funded Warrants”) at an exercise price of $0.00025 per share, of the Company. The Company has also granted to the several Underwriters an option to purchase up to 341,250 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Shares.” The shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants are herein referred to as the “Warrant Shares.” The Shares, the Warrant Shares and the Pre-Funded War
] Shares Connexa Sports Technologies Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • June 14th, 2022 • Connexa Sports Technologies Inc. • Sporting & athletic goods, nec • New York
Connexa Sports Technologies Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions of this underwriting agreement (this “Agreement”), to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ] shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the Underwriters an option to purchase up to [ ] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares are collectively referred to herein as the “Securities”.
4,700,000 Shares1 Lantronix, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • November 22nd, 2021 • Lantronix Inc • Computer communications equipment • New York
Lantronix, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,700,000 shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. TL Investment GmbH, a German limited liability company (the “Selling Stockholder”), has also granted to the Underwriters an option to purchase up to 705,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
3,750,000 Shares1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • October 14th, 2021 • NEUROONE MEDICAL TECHNOLOGIES Corp • Surgical & medical instruments & apparatus • New York
NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”) proposes to sell to Craig-Hallum Capital Group LLC (the “Underwriter”) an aggregate of 3,750,000 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company has also granted to the Underwriter an option to purchase up to 562,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
1,400,000 Shares1 Jerash Holdings (US), Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • October 4th, 2021 • Jerash Holdings (US), Inc. • Apparel & other finishd prods of fabrics & similar matl • New York
Jerash Holdings (US), Inc., a Delaware corporation (the “Company”), and Merlotte Enterprise Limited (the “Selling Stockholder”) propose to sell, acting severally and not jointly, to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,400,000 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company and the Selling Stockholder, acting severally and not jointly, have also granted to the Underwriters an option to purchase up to 210,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.” The aggregate number of Firm Shares that the Company and the Selling Stockholder are each selling is listed in Schedules I and II hereto.
4,720,000 Shares PLBY Group, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • June 14th, 2021 • PLBY Group, Inc. • Retail-miscellaneous retail • New York
PLBY Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,720,000 shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to 708,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3(b) hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
●] Shares PLBY Group, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • June 7th, 2021 • PLBY Group, Inc. • Retail-miscellaneous retail • New York
PLBY Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3(b) hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
●] Shares1 Anebulo Pharmaceuticals, Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3(b) hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
2,647,059 Shares1 Inotiv, Inc. Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • April 21st, 2021 • Inotiv, Inc. • Services-commercial physical & biological research • New York
Inotiv, Inc., an Indiana corporation (the “Company”), proposes to sell to Colliers Securities LLC (“you” or the “Underwriter”) an aggregate of 2,647,059 common shares (the “Firm Shares”) of the Company (the “Common Shares”). The Firm Shares consist of authorized but unissued Common Shares to be issued and sold by the Company. The Company also has granted to the Underwriter an option to purchase up to 397,058 additional Common Shares on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
6,015,000 Shares1 Full House Resorts, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • March 29th, 2021 • Full House Resorts Inc • Hotels & motels • New York
Full House Resorts, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,015,000 shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 902,250 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
11,111,111 Shares1 Phunware, Inc. Common Stock, $0.0001 par value per share UNDERWRITING AGREEMENTUnderwriting Agreement • February 16th, 2021 • Phunware, Inc. • Services-computer processing & data preparation • New York
Phunware, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 11,111,111 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 1,666,666 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities”. Notwithstanding anything to the contrary herein, the number of shares of the Securities shall not exceed 19.9% of the issued and outstanding securities prior to the offering.
1,783,500 Shares1 Limbach Holdings, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • February 10th, 2021 • Limbach Holdings, Inc. • Construction - special trade contractors • New York
Limbach Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,783,500 shares (the “Firm Shares”) of Common Stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 267,525 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
5,327,773 Shares1 REKOR SYSTEMS, INC. Common Stock, $0.0001 par value per share UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2021 • Rekor Systems, Inc. • Communications equipment, nec • New York
Rekor Systems, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,327,773 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 799,166 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (the “Agreement”) are herein collectively called the “Securities”.
UNDERWRITING AGREEMENTUnderwriting Agreement • October 6th, 2020 • Heritage Global Inc. • Services-business services, nec • New York
Heritage Global Inc., a Florida corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,750,000 shares (the “Firm Shares”) of Common Stock, $0.01 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 712,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Agreement are herein collectively called the “Securities”.
4,800,000 Shares PROCESSA PHARMACEUTICALS, INC. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENTUnderwriting Agreement • October 6th, 2020 • Processa Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
·] Shares1 Aziyo Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 30th, 2020 • Aziyo Biologics, Inc. • Biological products, (no disgnostic substances) • New York
Aziyo Biologics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [·] shares (the “Firm Shares”) of either Class A common stock, $0.001 par value per share (the “Class A common stock”), of the Company or, to the extent shares are purchased by entities affiliated with Deerfield Private Design Fund III, L.P., Class B common stock, $0.001 par value per share (the “Class B common stock” and, together with the Class A common stock, the “Common Stock”), of the Company. The Firm Shares consist of [·] authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to [·] additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (
●] Shares PROCESSA PHARMACEUTICALS, INC. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENTUnderwriting Agreement • September 17th, 2020 • Processa Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] authorized but unissued shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
1,600,000 Shares OrthoPediatrics Corp. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 18th, 2020 • Orthopediatrics Corp • Surgical & medical instruments & apparatus • New York
OrthoPediatrics Corp., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,600,000 shares (the “Firm Shares”) of Common Stock, $0.00025 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 240,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
11,797,752 Shares Warrants to Purchase 8,848,314 Shares CONTRAFECT CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 27th, 2020 • CONTRAFECT Corp • Pharmaceutical preparations • New York
ContraFect Corporation, a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) (i) an aggregate of 11,797,752 shares (the “Shares”) of common stock, $0.0001 par value per share (the “Common Stock”), of the Company and (ii) warrants to purchase up to an aggregate of 8,848,314 shares of Common Stock on the terms and conditions set forth in the form of warrant attached as Exhibit A hereto (the “Warrants”). Each Share is being sold together with a Warrant to purchase 0.75 shares of Common Stock at an exercise price of $4.90 per whole share of Common Stock. The aggregate number of shares of Common Stock underlying the Warrants are referred to herein as the “Warrant Shares.” The Shares, Warrants and Warrant Shares are collectively referred to in this Agreement as the “Securities.”
3,191,489 Shares ROCKWELL MEDICAL, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2020 • Rockwell Medical, Inc. • Electromedical & electrotherapeutic apparatus • New York
Rockwell Medical, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,191,489 shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 478,723 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
●] Shares[1] Allied Esports Entertainment, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • February 3rd, 2020 • Allied Esports Entertainment, Inc. • Services-amusement & recreation services • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • January 28th, 2020 • Itamar Medical Ltd. • Surgical & medical instruments & apparatus • New York
1,570,000 Shares OrthoPediatrics Corp. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 12th, 2019 • Orthopediatrics Corp • Surgical & medical instruments & apparatus • New York
OrthoPediatrics Corp., a Delaware corporation (the “Company”), and the stockholders of the Company listed in Schedule I hereto (the “Selling Stockholders”) severally propose to sell to the several Underwriters named in Schedule II hereto (the “Underwriters”) an aggregate of 1,570,000 shares (the “Firm Shares”) of Common Stock, $0.00025 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 1,520,000 authorized but unissued shares of Common Stock to be issued and sold by the Company and 50,000 outstanding shares of Common Stock to be sold by the Selling Stockholders. The Company has also granted to the several Underwriters an option to purchase up to 235,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
●] Shares SUPER LEAGUE GAMING, INC. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • February 12th, 2019 • Super League Gaming, Inc. • Services-amusement & recreation services • New York
2,103,702 Shares OPTIMIZERX CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • December 20th, 2018 • WPP PLC • Services-advertising agencies • New York
2,103,702 Shares OptimizeRx Corporation Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • December 18th, 2018 • OptimizeRx Corp • Services-business services, nec • New York
The selling shareholder named in Schedule I hereto (the “Selling Shareholder”) proposes to sell to the several Underwriters named in Schedule II hereto (the “Underwriters”) an aggregate of 2,103,702 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of OptimizeRx Corporation, a Nevada corporation (the “Company”). The Company has also granted to the several Underwriters an option to purchase up to 315,555 additional shares of Common Stock on the terms and for the purposes set forth in Section 4 hereof (collectively, the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
UNDERWRITING AGREEMENTUnderwriting Agreement • December 11th, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
